AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and ...

同源康医药公布重大利好消息后的第一个交易日，也是该股被纳入港股通名单生效的第一天 在医药行业竞争日益激烈的当下，每一次新药披露临床试验数据都可能意味着现有药物市场格局的改变，如果一款新药能够通过“头对头”试验胜过现有的重磅药物，其商业前景将不可估量。当中国创新药企$同源康医药-B(02410)$宣称，旗下核心管线TY-9591在二期临床的“头对头”试验数据优于已经上市的“肺癌药王”奥希替尼时，投资 ...

AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its ...

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Results from the COCOON study showed that Rybrevant plus Lacluze reduced grade 2 or higher dermatologic events by 50% ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

Webcasts will be available at the start of the presentations on the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. Replays of the presentations will also be ...

B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.

New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...